Two circulating tumor cell (CTC) assays can predict which men with advanced prostate cancer are unlikely to benefit from anti-androgen therapies, researchers said in a June 4 presentation at ASCO 2018.
Reuters Health Information
Original Article: Assays Predict Non-responders to Advanced Prostate Cancer Therapies